Linker Design for the Antibody Drug Conjugates: A Comprehensive Review
Yaxin Lei1,2, Minglei Zheng1,2, Peng Chen1
1Henan Linker Technology Key Laboratory, College of Advanced Interdisciplinary Science and Technology, Henan University of Technology, NO. 100 Lianhua Street, Zhengzhou, 450001, China.
Abstract:
Inspired by the "magic bullet" concept proposed over a century ago, antibody-drug conjugates (ADCs) are developed to enhance cancer therapy by linking monoclonal antibodies to a cytotoxic payload, aiming to overcome the limitations of conventional chemotherapy. To date, 17 ADCs have received regulatory approval for treating both hematologic and solid tumors. Despite their clinical success, developing ADCs with optimal therapeutic potential remains challenging. While selecting the appropriate antibody and cytotoxin is crucial, the linker plays a pivotal role in determining plasma stability and efficient payload release at the tumor site. Over the past decade, advances in linker technology have significantly improved the pharmacokinetics, efficacy, and toxicity profiles of ADCs. This review provides an overview of clinically validated linkers and recent innovations in linker design, focusing on drug release triggers, bioconjugation strategies, the impact of spacers on hydrophilicity, traceless drug release, and linker architecture, as well as a discussion of the bystander effect, offering insights for the rational design of next-generation ADCs.
Insights
Antibody-drug conjugates (ADCs) offer targeted cancer therapy. Advances in linker technology are key to improving ADC efficacy and safety for next-generation treatments.
Area of Science:
- Oncology
- Pharmacology
- Bioconjugation Chemistry
Background:
- Antibody-drug conjugates (ADCs) represent a targeted cancer therapy approach, combining monoclonal antibodies with cytotoxic payloads to overcome conventional chemotherapy limitations.
- Seventeen ADCs are currently approved for treating hematologic and solid tumors, demonstrating clinical success but highlighting ongoing challenges in optimizing therapeutic potential.
- The linker component is critical for ADC performance, influencing plasma stability and targeted payload release at the tumor site.
Purpose of the Study:
- To provide an overview of clinically validated linker technologies in antibody-drug conjugates (ADCs).
- To discuss recent innovations in ADC linker design, focusing on critical parameters for enhanced therapeutic outcomes.
- To offer insights for the rational design of next-generation ADCs through an analysis of linker strategies and their effects.
Main Methods:
- Review of clinically approved linkers and emerging linker technologies in antibody-drug conjugate (ADC) development.
- Analysis of linker design elements including drug release triggers, bioconjugation strategies, spacer impact on hydrophilicity, traceless release, and overall architecture.
- Discussion of the bystander effect in the context of ADC linker function.
Main Results:
- Advances in linker technology over the past decade have significantly improved the pharmacokinetic, efficacy, and toxicity profiles of ADCs.
- Specific linker design features, such as drug release mechanisms and spacer properties, directly impact ADC performance.
- Understanding linker characteristics is essential for maximizing the therapeutic index of ADCs.
Conclusions:
- Linker technology is a pivotal determinant of antibody-drug conjugate (ADC) success, complementing antibody and payload selection.
- Innovations in linker design offer promising avenues for developing more effective and safer ADCs.
- Further research into linker strategies, including the bystander effect, will guide the development of superior next-generation cancer therapies.
More Related Videos
08:47Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates
Published on: March 6, 2019
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
Related Concept Videos
00:49Ligand Binding and Linkage
01:10Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
01:14Phase II Conjugation Reactions: Overview
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...